It's unlikely that the underlying aligner would have run at different speeds on different systems since they're both going to be calling out to the same code. It seems more likely that the aligners were run with different parameters (different levels of multi-threading, different alignment stringencies etc) which can have a big effect on how long they take to process their data.
-
-
No, I ran them with the exact same parameters.Comment
-
I think that CLC GW is pretty good - we've had it hear for over a year.Comment
-
Strand NGS, the integrated analysis platform
Strand NGS (Formerly Avadis NGS) is an integrated platform that provides analysis, management and visualization tools for next-generation sequencing data. It supports extensive workflows for alignment, RNA-Seq, small RNA-Seq, DNA-Seq, Methyl-Seq, MeDIP-Seq, and ChIP-Seq experiments.
Pipeline manager option can be used to streamline large scale analysis.
More details on various enhancements/features can be found at http://www.strand-ngs.com/featuresComment
-
Strand NGS has improved a lot. The user interface is similar to that of Agilent Technologies GeneSpring, since it is built on same platform Avadis. Strand NGS is very flexible, since its interface auto-adopts to experiment type, only showing relevant analysis steps and functions (i.e guided workflows). You can also customize via R scripts and Jython scripts. Annotation Manager provides access to annotations from within the tool and many moreComment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment